Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019115417) OLIGONUCLEOTIDES FOR MODULATING RB1 EXPRESSION
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2019/115417 International Application No.: PCT/EP2018/084077
Publication Date: 20.06.2019 International Filing Date: 10.12.2018
IPC:
C12N 15/113 (2010.01) ,A61K 31/7088 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
113
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
70
Carbohydrates; Sugars; Derivatives thereof
7088
Compounds having three or more nucleosides or nucleotides
Applicants:
ROCHE INNOVATION CENTER COPENHAGEN A/S [DK/DK]; Fremtidsvej 3 2970 Hørsholm, DK
Inventors:
HAGEDORN, Peter; DK
PEDERSEN, Lykke; DK
Agent:
RUDOLPH HANSEN, Marianne; CH
Priority Data:
17206565.812.12.2017EP
Title (EN) OLIGONUCLEOTIDES FOR MODULATING RB1 EXPRESSION
(FR) OLIGONUCLÉOTIDES POUR LA MODULATION DE L'EXPRESSION DE RB1
Abstract:
(EN) The present invention relates to antisense oligonucleotides that are capable of modulating expression of RB1 in a target cell. The oligonucleotides hybridize to RB1 pre-mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment neurological injury or neuronal degeneration using the oligonucleotide.
(FR) La présente invention concerne des oligonucléotides antisens qui sont capables de moduler l'expression de RB1 dans une cellule cible. Les oligonucléotides s'hybrident au pré-ARNm de RB1. La présente invention concerne également des conjugués de l'oligonucléotide ainsi que des compositions pharmaceutiques et des méthodes de traitement de lésions neurologiques ou de la dégénérescence neuronale au moyen de l'oligonucléotide.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)